Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$51.62 USD

51.62
1,305,103

-0.26 (-0.50%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $51.63 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.

Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View

by Zacks Equity Research

JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.

Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

by Zacks Equity Research

FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

by Zacks Equity Research

APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised

by Zacks Equity Research

Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 24.06% and 90.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.

CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?

Perrigo to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Regeneron to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.36, representing a -1.23% change from its previous close.

Ahan Chakraborty headshot

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

by Ahan Chakraborty

FULC is expected to provide updates on its early-stage candidate for SCD, pociredir, in its third-quarter earnings release.

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

by Zacks Equity Research

Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

by Ekta Bagri

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know

by Zacks Equity Research

INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, indicating a -0.84% shift from the previous trading day.

Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 67.5% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

Ahan Chakraborty headshot

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

by Ahan Chakraborty

Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.